关于利妥昔单抗在类风湿关节炎患者中应用的共识声明。
Consensus statement on the use of rituximab in patients with rheumatoid arthritis.
作者信息
Smolen J S, Keystone E C, Emery P, Breedveld F C, Betteridge N, Burmester G R, Dougados M, Ferraccioli G, Jaeger U, Klareskog L, Kvien T K, Martin-Mola E, Pavelka K
机构信息
Department of Rheumatology, Third Department of Internal Medicine, Medical University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria.
出版信息
Ann Rheum Dis. 2007 Feb;66(2):143-50. doi: 10.1136/ard.2006.061002. Epub 2006 Oct 26.
Abstract
A large number of experts experienced in the treatment of rheumatoid arthritis were involved in formulating a consensus statement on the use of B cell-targeted treatment with rituximab in patients with rheumatoid arthritis. The statement was supported by data from randomised controlled clinical trials and the substantial literature on oncology. The statement underwent three rounds of discussions until its ultimate formulation. It should guide clinicians in the use of this newly approved biological agent in treating patients with rheumatoid arthritis.
摘要
众多在类风湿关节炎治疗方面经验丰富的专家参与制定了关于在类风湿关节炎患者中使用利妥昔单抗进行B细胞靶向治疗的共识声明。该声明得到了随机对照临床试验数据以及大量肿瘤学文献的支持。该声明经过三轮讨论才最终形成。它应指导临床医生在治疗类风湿关节炎患者时使用这种新批准的生物制剂。
相似文献
1
Consensus statement on the use of rituximab in patients with rheumatoid arthritis.关于利妥昔单抗在类风湿关节炎患者中应用的共识声明。
Ann Rheum Dis. 2007 Feb;66(2):143-50. doi: 10.1136/ard.2006.061002. Epub 2006 Oct 26.
2
Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis.类风湿关节炎患者应用利妥昔单抗的更新共识声明。
Ann Rheum Dis. 2011 Jun;70(6):909-20. doi: 10.1136/ard.2010.144998. Epub 2011 Mar 6.
3
[Rituximab treatment of rheumatoid arthritis: new evidence].[利妥昔单抗治疗类风湿关节炎：新证据]
Ter Arkh. 2009;81(6):82-91.
4
[Rituximab in patients with rheumatoid arthritis: systematic review].[利妥昔单抗治疗类风湿关节炎患者：系统评价]
Orv Hetil. 2007 Oct 7;148(40):1883-93. doi: 10.1556/OH.2007.28080.
5
B cell therapy for rheumatoid arthritis: the rituximab (anti-CD20) experience.类风湿关节炎的B细胞疗法：利妥昔单抗（抗CD20）的应用经验
Ann Rheum Dis. 2003 Nov;62 Suppl 2(Suppl 2):ii55-9. doi: 10.1136/ard.62.suppl_2.ii55.
6
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007.《2007年关于治疗风湿性疾病生物制剂的更新共识声明》
Ann Rheum Dis. 2007 Nov;66 Suppl 3(Suppl 3):iii2-22. doi: 10.1136/ard.2007.081430.
7
Use of rituximab for the treatment of rheumatoid arthritis: the Latin American context.利妥昔单抗在类风湿关节炎治疗中的应用：拉丁美洲背景
Rheumatology (Oxford). 2008 Jul;47(7):1097-9. doi: 10.1093/rheumatology/ken015a. Epub 2008 May 7.
8
Rituximab fixed retreatment versus on-demand retreatment in refractory rheumatoid arthritis: comparison of two B cell depleting treatment strategies.利妥昔单抗固定再治疗与按需再治疗用于难治性类风湿关节炎：两种B细胞清除治疗策略的比较
Ann Rheum Dis. 2009 Jun;68(6):1075-7. doi: 10.1136/ard.2008.100438.
9
Rituximab treatment in rheumatoid arthritis: how does it work?类风湿关节炎的利妥昔单抗治疗：它是如何发挥作用的？
Arthritis Res Ther. 2009;11(6):134. doi: 10.1186/ar2852. Epub 2009 Nov 24.
10
Clinical outcome and B cell depletion in patients with rheumatoid arthritis receiving rituximab monotherapy in comparison with patients receiving concomitant methotrexate.类风湿关节炎患者接受利妥昔单抗单药治疗与接受甲氨蝶呤联合治疗的临床结局及B细胞耗竭情况比较
Ann Rheum Dis. 2008 Nov;67(11):1648-9. doi: 10.1136/ard.2007.087023.
引用本文的文献
1
Rituximab induced lung injury.利妥昔单抗诱发的肺损伤。
BMC Pulm Med. 2025 Jul 28;25(1):359. doi: 10.1186/s12890-025-03802-x.
2
Rituximab, Apremilast, and Upadacitinib as Selected Biosimilar and Targeted Synthetic Disease-Modifying Antirheumatic Drugs with Diverse Mechanisms of Action: Their Current Use in Slowing Down the Progression of Disease.利妥昔单抗、阿普米司特和乌帕替尼作为具有不同作用机制的选定生物类似药和靶向合成改善病情抗风湿药：它们目前在减缓疾病进展方面的应用。
J Clin Med. 2025 Apr 10;14(8):2605. doi: 10.3390/jcm14082605.
3
Evaluation of pediatric rheumatologists' approach to rituximab use: a questionnaire study.评估儿科风湿病学家使用利妥昔单抗的方法：一项问卷调查研究。
Eur J Pediatr. 2024 Sep;183(9):3959-3968. doi: 10.1007/s00431-024-05654-9. Epub 2024 Jun 26.
4
Emerging Therapeutic Options for Refractory Pulmonary Sarcoidosis: The Evidence and Proposed Mechanisms of Action.难治性肺结节病的新兴治疗选择：证据及拟议的作用机制
J Clin Med. 2023 Dec 19;13(1):15. doi: 10.3390/jcm13010015.
5
Rituximab exerts its anti-arthritic effects via inhibiting NF-κB/GM-CSF/iNOS signaling in B cells in a mouse model of collagen-induced arthritis.在胶原诱导性关节炎小鼠模型中，利妥昔单抗通过抑制B细胞中的NF-κB/GM-CSF/iNOS信号传导发挥其抗关节炎作用。
Heliyon. 2023 May 25;9(6):e16673. doi: 10.1016/j.heliyon.2023.e16673. eCollection 2023 Jun.
6
Interstitial Lung Disease in Mixed Connective Tissue Disease: An Advanced Search.混合性结缔组织病中的间质性肺疾病：一项高级检索
Cureus. 2023 Mar 15;15(3):e36204. doi: 10.7759/cureus.36204. eCollection 2023 Mar.
7
Rituximab for thyroid-associated ophthalmopathy.利妥昔单抗治疗甲状腺相关眼病。
Cochrane Database Syst Rev. 2022 Jun 16;6(6):CD009226. doi: 10.1002/14651858.CD009226.pub3.
8
Insights Into the Concept of Rheumatoid Arthritis Flare.类风湿关节炎发作概念的见解。
Front Med (Lausanne). 2022 Mar 17;9:852220. doi: 10.3389/fmed.2022.852220. eCollection 2022.
9
Interactions of B-lymphocytes and bone cells in health and disease.B 淋巴细胞与骨细胞在健康与疾病中的相互作用。
Bone. 2023 Mar;168:116296. doi: 10.1016/j.bone.2021.116296. Epub 2021 Dec 21.
10
Hypersensitivity reactions to monoclonal antibodies: Classification and treatment approach (Review).单克隆抗体的超敏反应：分类与治疗方法（综述）
Exp Ther Med. 2021 Sep;22(3):949. doi: 10.3892/etm.2021.10381. Epub 2021 Jul 3.
本文引用的文献
1
Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.利妥昔单抗治疗对抗肿瘤坏死因子疗法难治的类风湿性关节炎：一项多中心、随机、双盲、安慰剂对照的III期试验结果，评估24周时的主要疗效和安全性。
Arthritis Rheum. 2006 Sep;54(9):2793-806. doi: 10.1002/art.22025.
2
Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma.CHOP联合利妥昔单抗治疗HIV相关非霍奇金淋巴瘤的II期试验。
J Clin Oncol. 2006 Sep 1;24(25):4123-8. doi: 10.1200/JCO.2005.05.4684. Epub 2006 Aug 8.
3
The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial.利妥昔单抗用于尽管接受甲氨蝶呤治疗但仍患有活动性类风湿性关节炎患者的疗效和安全性：一项IIB期随机、双盲、安慰剂对照、剂量范围试验的结果
Arthritis Rheum. 2006 May;54(5):1390-400. doi: 10.1002/art.21778.
4
Patients' views on the quality of health care for rheumatoid arthritis.患者对类风湿关节炎医疗质量的看法。
Rheumatology (Oxford). 2006 Dec;45(12):1522-8. doi: 10.1093/rheumatology/kel132. Epub 2006 Apr 21.
5
The definition and measurement of disease modification in inflammatory rheumatic diseases.炎症性风湿性疾病中疾病修饰的定义与测量
Rheum Dis Clin North Am. 2006 Feb;32(1):9-44, vii. doi: 10.1016/j.rdc.2005.09.005.
6
Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy.抗癌治疗期间乙型肝炎病毒再激活的诊断、预防及管理
Hepatology. 2006 Feb;43(2):209-20. doi: 10.1002/hep.21051.
7
Treatment of rheumatoid arthritis.类风湿关节炎的治疗。
BMJ. 2006 Jan 21;332(7534):152-5. doi: 10.1136/bmj.332.7534.152.
8
EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).欧洲抗风湿病联盟（EULAR）早期关节炎管理建议：国际临床研究包括治疗学欧洲常务委员会（ESCISIT）特别工作组报告
Ann Rheum Dis. 2007 Jan;66(1):34-45. doi: 10.1136/ard.2005.044354. Epub 2006 Jan 5.
9
Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial.早期类风湿关节炎患者四种不同治疗策略的临床和影像学结果（BeSt研究）：一项随机对照试验
Arthritis Rheum. 2005 Nov;52(11):3381-90. doi: 10.1002/art.21405.
10
Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005.《2005年关于生物制剂，特别是肿瘤坏死因子α（TNFα）阻断剂和白细胞介素-1受体拮抗剂（IL-1ra）治疗风湿性疾病的更新共识声明》
Ann Rheum Dis. 2005 Nov;64 Suppl 4(Suppl 4):iv2-14. doi: 10.1136/ard.2005.044941.
Zotero 插件